Press Releases BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Real-time Estimate Cboe BZX Other stock markets 12:49:20 2024-05-13 pm EDT			5-day change	1st Jan Change
5.465 ^USD	+2.73%		+3.70%	-8.76%

04:37pm	BioCryst Says Orladeyo Granted Approval in Mexico	MT
May. 09	BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ORLADEYO® (berotralstat) Approved in Mexico	07:01am	AQ
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)	May. 09	AQ
BioCryst to Present at Upcoming Investor Conferences	May. 07	AQ
BioCryst Pharmaceuticals, Freshpet rise; Luminar, Integra fall, Monday, 5/6/2024	May. 06	AQ
BioCryst: Q1 Earnings Snapshot	May. 06	AQ
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update	May. 06	AQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 03	AQ
BioCryst to Report First Quarter 2024 Financial Results on May 6	Apr. 22	AQ
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency	Apr. 17	AQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 03	AQ
BioCryst to Present at Upcoming Investor Conferences	Mar. 25	AQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 05	AQ
BioCryst: Q4 Earnings Snapshot	Feb. 26	AQ
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones	Feb. 26	AQ
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment	Feb. 23	AQ
BioCryst to Present at Upcoming Investor Conferences	Feb. 21	AQ
BioCryst Launches ORLADEYO® (berotralstat) in Italy	Feb. 19	AQ
BioCryst to Report Fourth Quarter 2023 Financial Results on February 26	Feb. 12	AQ
BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting	Feb. 05	AQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Press Releases

Filters